810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide...
810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide with PD-1 blockade
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundNovel therapy combinations utilizing PD-1 immune checkpoint inhibition have improved outcomes in patients with RCC; however, positive clinical responses are limited to select individuals.1 Various studies indicate resistance is mediated partly through STAT3 induced activity and a concomitant accumulation of tumor infiltrating myeloid deri...
Alternative Titles
Full title
810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide with PD-1 blockade
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2840708176
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2840708176
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-SITC2022.0810
